Therapeutic or Preventive Procedure – Page 70

Intellia Therapeutics Advances in Hereditary Angioedema Treatment with Durable One-Dose CRISPR Gene Editing Therapy

11 months ago talkbio0Tagged Angioedemas, Hereditary, Clinical Trials, Clustered Regularly Interspaced Short Palindromic Repeats, Gene Modification, Intellia, Long-term, single-dose

Intellia Therapeutics, Hereditary Angioedema (HAE), CRISPR Gene Editing, NTLA-2002, Single-Dose Treatment, Long-Term Data, Clinical Trials

Bionova Scientific Expands into Plasmid DNA Services for Cell and Gene Therapy Developers

11 months ago talkbio0Tagged Asahi Kasei, Biological Factors, Bionova, CDMO, Cells, DNA, Facility (object), gene therapy, Plasmids, Science, Texas

Bionova Scientific, Plasmid DNA, Cell and Gene Therapy, CDMO, Asahi Kasei Group, Biopharmaceuticals, Biologics, Texas Facility

ASCO 2024: Bristol Myers Squibb’s Opdivo-Yervoy Combo Challenges Roche and AstraZeneca in First-Line Liver Cancer Treatment

11 months ago talkbio0Tagged 2024, ASCO, AstraZeneca, CheckMate-9DW, first-line, Immunotherapy, Liver and Intrahepatic Biliary Tract Carcinoma, Myers, Opdivo-Yervoy, Roche (company), squibb

ASCO 2024, Opdivo-Yervoy, Bristol Myers Squibb, Liver Cancer, First-Line Treatment, Roche, AstraZeneca, Immunotherapy, CheckMate-9DW

Structure Therapeutics’ Oral GLP-1 Achieves Comparable Weight Loss to Lilly’s Candidate

11 months ago talkbio0Tagged Eli Lilly, Glucagon-Like Peptide 1, Obesity, Oral Candidate, Structure, Weight Loss

Structure Therapeutics, GLP-1, Obesity, Weight Loss, Lilly, Oral Candidate

Biotech Faces a Reckoning: The Challenges and Shifts in Cell Therapies

11 months ago talkbio0Tagged acceptance, Autoimmune Diseases, Cell Therapy, Drug Industry, gene therapy, Manufacture, Market

cell therapy, biotech, gene therapy, autoimmune diseases, manufacturing challenges, market acceptance, pharmaceutical industry

Intellia Therapeutics Reports Promising Long-Term Data for Single-Dose HAE Therapy

11 months ago talkbio0Tagged Angioedemas, Hereditary, Clustered Regularly Interspaced Short Palindromic Repeats, Gene Modification, Intellia, Long-term, NTLA-2002, single-dose

Intellia Therapeutics, NTLA-2002, Hereditary Angioedema (HAE), CRISPR Gene Editing, Single-Dose Treatment, Long-Term Data

BMS Details Confirmatory Trial Win for KRAS Inhibitor Krazati

11 months ago talkbio0Tagged Accelerated, Approved, Confirmatory Trial, Inhibitor, K-ras Oncogene, KRAZATI, Myers, Non-Small Cell Lung Carcinoma, Pharmacotherapy, Progression-Free Survival, squibb, United States Food and Drug Administration

Bristol Myers Squibb, Krazati, KRAS inhibitor, confirmatory trial, non-small cell lung cancer (NSCLC), progression-free survival (PFS), chemotherapy, accelerated approval, FDA

Gilead’s Trodelvy Fails to Meet Primary Endpoint in Lung Cancer Trial, but Shows Promise in Subgroup Analysis ###

11 months ago talkbio0Tagged ASCO, Clinical Trials, Directed Antibody-Drug Conjugate, Gilead Sciences, Immunotherapy, Malignant neoplasm of lung, Neoplasms, TACSTD2 protein, human, Trodelvy, United States Food and Drug Administration

Gilead Sciences, Trodelvy, Lung Cancer, ASCO, FDA, Clinical Trials, Oncology, Immunotherapy, Trop-2 Directed Antibody-Drug Conjugate

Ultragenyx Advances Gene Therapy for Glycogen Storage Disease Type Ia Following Phase 3 Success

11 months ago talkbio0Tagged DTX401, gene therapy, GlucoGene, Glycogen storage disease type Ia, Hereditary Diseases, Phase 3 Clinical Trials, Ultragenyx

Ultragenyx, gene therapy, glycogen storage disease type Ia, DTX401, Phase 3 study, GlucoGene, rare genetic diseases

Early Detection and Personalized Treatment of Colorectal Cancer: The Promise of Whole Genome Sequencing-Based Circulating Tumor DNA Tracking” ###

11 months ago talkbio0Tagged Adjuvant Therapy, Circulating, Circulating Tumor DNA, Colorectal Carcinoma, Detection, Liquid Biopsy, Molecular residual disease, MRD, Personalized Treatment, Whole Genome Sequencing

Circulating tumor DNA (ctDNA), Whole genome sequencing (WGS), Colorectal cancer, Early detection, Personalized treatment, Adjuvant therapy, Molecular residual disease (MRD), Liquid biopsies